Recombinant human interleukin-11 (Shanghai Zhangjiang)

重组人白介素-11（上海张江生物）

Report date: 2022/02/21 14:11:48

Base Information

Drug NameRecombinant human interleukin-11 (Shanghai Zhangjiang)
Drug Alias Name注射用重组人白介素-11（上海张江生物）重组人白介素11（上海张江生物）
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin 11 receptor alpha stimulants
TargetsInterleukin 11 receptor alpha
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsThrombocytopenia

Other Information

ATC CodeN/A
Related LinksN/A